Enlivex Therapeutics Ltd (ENLV) — Cash Flow-to-Debt Ratio
Enlivex Therapeutics Ltd (ENLV) has a Cash Flow-to-Debt Ratio of -0.66x as of September 2025, meaning its operating cash flow of ILA-2.30 Million could theoretically repay -1% of its total liabilities (ILA3.46 Million) in one year. See Enlivex Therapeutics Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Enlivex Therapeutics Ltd Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Enlivex Therapeutics Ltd across 13 annual periods. Also explore Enlivex Therapeutics Ltd net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Enlivex Therapeutics Ltd (2012–2024)
Year-by-year debt coverage analysis for Enlivex Therapeutics Ltd. For market capitalisation and broader financial context, see market value of Enlivex Therapeutics Ltd.
| Year | CF-to-Debt Ratio | Operating CF (ILA) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -3.17x | ILA-13.01 Million | ILA4.10 Million | ▲ +9.0% |
| 2023 | -3.49x | ILA-23.52 Million | ILA6.75 Million | ▼ -57.2% |
| 2022 | -2.22x | ILA-23.95 Million | ILA10.80 Million | ▼ -27.8% |
| 2021 | -1.74x | ILA-17.54 Million | ILA10.11 Million | ▲ +23.2% |
| 2020 | -2.26x | ILA-11.01 Million | ILA4.87 Million | ▼ -101.5% |
| 2019 | -1.12x | ILA-7.04 Million | ILA6.28 Million | ▲ +52.9% |
| 2018 | -2.38x | ILA-3.16 Million | ILA1.33 Million | ▲ +82.8% |
| 2017 | -13.81x | ILA-6.35 Million | ILA460.00K | ▼ -72.2% |
| 2016 | -8.02x | ILA-15.49 Million | ILA1.93 Million | ▼ -56.4% |
| 2015 | -5.13x | ILA-13.25 Million | ILA2.58 Million | ▼ -165.1% |
| 2014 | -1.93x | ILA-4.41 Million | ILA2.28 Million | ▲ +70.7% |
| 2013 | -6.60x | ILA-865.00K | ILA131.00K | ▼ -259.0% |
| 2012 | -1.84x | ILA-149.00K | ILA81.00K | — |